Evidence map›Paper›PMID 42079647›Full record

ArticleFrontiers in immunology2026

Engineering human Tregs to resist tacrolimus via FKBP12 gene editing.

Christopher J Requejo Cier, Nicolas Valentini, Gabrielle Boudreau, Jean-Sébastien Delisle, Caroline Lamarche

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Christopher J Requejo CierCentre de recherche de l'Hôpital Maisonneuve-Rosemont, Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC, Canada.
Nicolas ValentiniCentre de recherche de l'Hôpital Maisonneuve-Rosemont, Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, QC, Canada.
Gabrielle BoudreauCentre de recherche de l'Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada.
Jean-Sébastien DelisleCentre de recherche de l'Hôpital Maisonneuve-Rosemont, Department of Medicine, Université de Montréal, Montreal, QC, Canada.
Caroline LamarcheCentre de recherche de l'Hôpital Maisonneuve-Rosemont, Department of Medicine, Université de Montréal, Montreal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulatory T cells (Tregs) are essential for immune tolerance and are under active development as cell therapy in transplantation. However, the widespread use of the calcineurin inhibitor tacrolimus may inadvertently suppress Treg proliferation and activation, undermining their therapeutic potential. Tacrolimus binds to the FKBP12 protein in T cells, forming a complex that blocks calcineurin-NFAT signaling and suppresses IL-2 gene transcription, thereby inhibiting T cell activation. In this study, we investigated whether deleting FKBP12 in human Tregs could prevent tacrolimus-mediated suppression. Using CRISPR-Cas9 gene editing, FKBP12 was knocked out in

Indexed as

Gene EditingImmunosuppressive AgentsTacrolimusTacrolimus Binding Protein 1AT-Lymphocytes, RegulatoryCell ProliferationCells, CulturedCRISPR-Cas SystemsHumansInterleukin-2Lymphocyte ActivationImmunosuppressive AgentsInterleukin-2TacrolimusTacrolimus Binding Protein 1ACRISPR-Cas9FKBP12immunotherapyregulatory T cells (Tregs)tacrolimus

Identifiers

PMID42079647
PMCPMC13133020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.